|

BMS-986507 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Iza-bren, Izalontamab brengitecan

Pipeline

Phase 1/2: 1

Top Sponsors

  • Bristol-Myers Squibb1

Indications

  • Lung Cancer1
  • Breast Cancer1
  • Cancer1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.